A protamine filter for extracorporeal heparin removal. Development, testing, blood compatibility evaluation, and...

Area of Science:

• Biomedical Engineering
• Cardiovascular Research
• Materials Science

Background:

• Heparin is crucial for preventing blood clots during extracorporeal perfusion but requires removal post-procedure.
• Existing heparin removal methods have limitations.
• Protamine is a known heparin antagonist.

Purpose of the Study:

• To evaluate the efficacy and biocompatibility of a novel protamine filter for heparin removal.
• To assess the filter's impact on coagulation, complement system, and antithrombin III levels.

Main Methods:

• In vivo canine studies using a protamine filter device.
• Measurement of heparin removal efficiency and blood circuit time.
• Assessment of hemodynamic and thrombocytopenic responses.
• Evaluation of biocompatibility via coagulation cascade, complement system, and antithrombin III assays.

Main Results:

• The protamine filter removed over 50% of heparin in under 20 minutes in dogs.
• No significant protamine-induced hemodynamic or thrombocytopenic responses were observed.
• Adsorbed heparin retained partial activity, rendering the surface antithrombotic.
• Minimal complement activation compared to untreated membranes.
• No depletion of circulating antithrombin III.

Conclusions:

• The protamine filter is an effective and biocompatible device for heparin removal during extracorporeal perfusion.
• The filter demonstrates a favorable safety profile with minimal impact on coagulation and complement systems.
• Future developments may include a dual-filter system with biofeedback for enhanced heparin management.